2023 World Conference on Lung Cancer (Posters)-EP12.01. Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Cell Lung Cancer in Vietnam

EP12.01. Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Cell Lung Cancer in Vietnam - PDF(Abstract)

Back to course

Pdf Summary

A single-center real-world study conducted in Vietnam evaluated the effectiveness and tolerability of the second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), afatinib, as a first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). The study analyzed data from 100 patients who initiated first-line afatinib treatment between January 2018 and June 2022. The primary outcome measured was time to treatment failure (TTF), while secondary outcomes included objective response rate (ORR), disease control rate (DCR), and overall survival (OS). <br /><br />The study found that the median TTF was 17.5 months, with no significant difference between patients with or without baseline brain metastases. However, patients with liver metastases had a numerically worse outcome than those without liver involvement. Among patients with measurable lesions, the ORR and DCR were 60% and 100% respectively, while the median OS was not reached. The 1-year and 2-year OS rates were 87% and 72% respectively.<br /><br />The most common side effects of afatinib were rash/acne, diarrhea, paronychia, and stomatitis. However, only 21% of patients experienced grade 3 side effects, and only three patients had to discontinue afatinib due to adverse effects.<br /><br />Overall, the study suggests that first-line afatinib treatment is effective and well-tolerated in Vietnamese patients with EGFR-mutated NSCLC. It demonstrates encouraging survival outcomes, a high response rate, a low incidence of intracranial progression, and a manageable tolerability profile. The study also indicates that further research is needed to investigate the prognostic value of liver metastasis in NSCLC patients with EGFR mutations.

Asset Subtitle

Chau Pham

Meta Tag

Speaker Chau Pham

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Vietnam

real-world study

epidermal growth factor receptor

EGFR-tyrosine kinase inhibitor

afatinib

first-line treatment

non-small cell lung cancer

time to treatment failure

objective response rate

overall survival